Drug Trial Radar · NCT06624644
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
135
Planned (sponsor's estimate)
Start
Aug 6, 2025
Primary completion
Feb 2029
Study completion Feb 2031
Sponsor
- Lead sponsor
- Linnaeus Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during which melanoma does not grow or spread after starting treatment with LNS8801? Researchers will compare LNS8801 taken alone or LNS8801 taken together with another drug called pembrolizumab to other therapies as decided by the treating doctor. 135 patients will be randomly (like flipping a coin) placed in 3 treatment groups. In the first group (LNS8801 only) - Patients will take 125mg tablet of LNS8801 by mouth once per day every day for up to 2 years. In the second group (LNS8801 + pembrolizumab) - Patients will take 125mg tablet of LNS8801 by mouth once per day plus 200 mg of pembrolizumab by IV infusion once every 3 weeks for up to 2 years. In the third group, called Physician's Choice (PC), patients will receive chemotherapy (dacarbazine or temozolomide) or immunotherapy (pembrolizumab, nivolumab/relatlimab or nivolumab/ipilimumab) as determined by their treating physician. How often the patient visits the clinic visits will depend on the treatment group. Besides returning to the clinic for treatment, the patient will undergo periodic safety assessments and other required study procedures such as imaging assessments.
Conditions
- Melanoma (Skin Cancer)
- Melanoma Stage IIIB-IV
- Cutaneous Melanoma
- Unresectable Melanoma
Interventions
LNS8801Biological
G protein-coupled estrogen receptor (GPER) agonist
PembrolizumabBiological
Recombinant monoclonal antibody (anti-PD1)
Chemotherapy (dacarbazine or temozolomide)Drug
chemotherapy (dacarbazine, temozolomide)
Immunotherapy (Pembrolizumab)Biological
pembrolizumab
Immunotherapy (nivolumab and relatlimab)Biological
nivolumab and relatlimab
Immunotherapy (ipilimumab and nivolumab)Biological
ipilimumab and nivolumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare progression-free survival (PFS) of LNS8801 + pembrolizumab vs PC arms as assessed by RECIST v1.1.Time frame: up to 2 years.
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
USC Newport Beach
Newport Beach, California · Recruiting
UCSF
San Francisco, California · Recruiting
Stanford
Stanford, California · Recruiting
University of Colorado Anschutz
Aurora, Colorado · Recruiting
University of Colorado
Denver, Colorado · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Dana Farber
Boston, Massachusetts · Recruiting
University of New Mexico
Albuquerque, New Mexico · Recruiting
UPenn
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.